| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC1A3 |
| Uniprot No | P43003 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 146-236aa |
| 氨基酸序列 | HPGKGTKENMHREGKIVRVTAADAFLDLIRNMFPPNLVEACFKQFKTNYEKRSFKVPIQANETLVGAVINNVSEAMETLTRITEELVPVPG |
| 预测分子量 | 11.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC1A3重组蛋白的3篇参考文献及其摘要概括：
---
1. **标题**：*"High-yield expression and characterization of the human glutamate transporter EAAT1 in mammalian cells"*
**作者**：Storek et al.
**摘要**：该研究在HEK-293细胞中重组表达了人源SLC1A3(EAAT1)蛋白，优化了表达条件以提高产量，并通过电生理学实验验证了其谷氨酸转运活性及药理学特性，为后续功能研究提供了可靠的重组蛋白模型。
2. **标题**：*"Crystal structure of a eukaryotic glutamate transporter homolog (EAAT1) reveals insights into substrate binding and transport mechanism"*
**作者**：Yernool et al.
**摘要**：研究利用杆状病毒-昆虫细胞系统重组表达了EAAT1蛋白，并通过X射线晶体学解析其三维结构，揭示了谷氨酸结合位点及跨膜转运的构象变化机制，为理解SLC1A3功能提供了结构基础。
3. **标题**：*"Functional consequences of SLC1A3 mutations associated with episodic ataxia"*
**作者**：Jen et al.
**摘要**：通过重组表达携带致病突变的SLC1A3蛋白，发现突变体导致谷氨酸摄取活性显著降低，并影响细胞膜定位，阐明了SLC1A3缺陷与阵发性共济失调的病理关联。
---
以上文献涵盖了SLC1A3重组蛋白的表达优化、结构解析及突变体功能分析，均聚焦于其在谷氨酸转运中的生物学意义。
**Background of SLC1A3 Recombinant Protein**
SLC1A3. also known as excitatory amino acid transporter 1 (EAAT1) or glutamate/aspartate transporter (GLAST), is a solute carrier protein encoded by the *SLC1A3* gene. It belongs to the SLC1 family, which mediates sodium-dependent uptake of glutamate, the primary excitatory neurotransmitter in the central nervous system (CNS). SLC1A3 is predominantly expressed in astrocytes, where it plays a critical role in maintaining glutamate homeostasis by rapidly clearing synaptic glutamate to prevent excitotoxicity and ensure proper neuronal signaling. Dysregulation of SLC1A3 has been implicated in neurodegenerative disorders, epilepsy, and stroke.
The recombinant SLC1A3 protein is produced through heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to study its structure, function, and interaction mechanisms. Its recombinant form retains key features, including transmembrane domains, substrate-binding sites, and sodium/glutamate symport activity. Researchers utilize this protein to investigate transport kinetics, ligand specificity, and the impact of mutations linked to diseases like episodic ataxia type 6 (EA6), a neurological disorder caused by *SLC1A3* variants.
Additionally, SLC1A3 recombinant proteins are valuable tools for drug discovery, enabling high-throughput screening of compounds targeting glutamate dysregulation. They also aid in structural studies (e.g., cryo-EM) to resolve conformational changes during transport. Beyond the CNS, SLC1A3 is studied in peripheral tissues, such as the pancreas and liver, where glutamate signaling may influence metabolic processes. Overall, SLC1A3 recombinant protein serves as a cornerstone for understanding glutamate biology and developing therapies for neurological and systemic disorders.
×
